|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.4108 - 0.4108|
|52 Week Range||0.2287 - 0.8371|
|Beta (5Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercial Services Agreement with Veru Inc. (Veru) for sabizabulin for COVID-19 in Canada. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death.
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2022.